Azaquinazoline Inhibitors Of Atypical Protein Kinase C
申请人:Ignyta, Inc.
公开号:US20150274720A1
公开(公告)日:2015-10-01
The present application provides a compound of formula (I)
and/or a salt thereof, wherein R
1
, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.
A new strategy is developed for the synthesis of 1-aminoisoquinoline derivatives. This Rh(III)-catalyzed [4 + 2] annulation reaction employs benzamidines as efficient directing groups and the vinylenecarbonate as an acetylene surrogate. Additionally, the reaction features broad substrate scopes and good yields, only producing carbonate anion as byproduct.
The present invention provides compounds having formula (I):
and pharmaceutically acceptable derivatives thereof, wherein R
1
-R
4
, n, p, A, B, D, E, L and AR
1
are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).